患者特异性可测量残留病灶标志物预测骨髓增生异常综合征及相关疾病患者造血干细胞移植后的结局
这项前瞻性观察研究纳入266例计划接受造血干细胞移植的骨髓增生异常综合征患者,用靶向二代测序联合微滴数字PCR追踪患者特异性突变。221例有MRD结果,44例复发中42例在临床复发前中位71天检出骨髓MRD阳性;MRD阳性与更短的无复发生存和总生存独立相关。
要点
- 骨髓MRD阳性常先于临床复发出现,中位提前71天。
- MRD阳性与更短无复发生存(HR 7.99)和总生存(HR 2.65)独立相关。
- 作者认为二代测序联合微滴数字PCR评估个体化MRD可行,可用于早期发现复发。
核心结论
- 采用二代测序联合微滴数字PCR评估个体化MRD是可行的,可用于早期发现复发;MRD阳性与更短的无复发生存和总生存相关。
研究设计与样本
- 前瞻性观察性研究,纳入计划接受造血干细胞移植的骨髓增生异常综合征患者,共266例。
- 收集骨髓和外周血样本直至复发、死亡或移植后24个月研究结束,用靶向二代测序 panel 识别患者特异性突变并以微滴数字PCR追踪。
主要发现
- 266例患者移植后3年估计无复发生存率和总生存率分别为59%和64%。
- 44例有完整MRD数据的复发中42例在复发前检出骨髓MRD阳性,中位提前71天(范围23-283天)。
- 137例持续完全缓解患者中93例持续MRD阴性、39例由MRD阳性转为阴性、5例末次采样时MRD阳性。
- 首次MRD阳性后1年估计无复发生存率在 cutoff 0.1%、0.3%、0.5%时分别为49%、39%、30%。
- 多因素Cox模型中,MRD(HR 7.99)、WHO亚组AML(HR 4.87)、TP53 multi-hit(HR 2.38)、NRAS(HR 3.55)、急性GVHD III-IV级(HR 4.13)与更短无复发生存相关;MRD阳性也与更短总生存独立相关(HR 2.65)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Clinical relapse is the major threat for patients with myelodysplastic syndrome (MDS) undergoing hematopoietic stem-cell transplantation (HSCT). Early detection of measurable residual disease (MRD) would enable preemptive treatment and potentially reduced relapse risk. METHODS: Patients with MDS planned for HSCT were enrolled in a prospective, observational study evaluating the association between MRD and clinical outcome. We collected bone marrow (BM) and peripheral blood samples until relapse, death, or end of study 24 months after HSCT. Patient-specific mutations were identified with targeted next-generation sequencing (NGS) panel and traced using droplet digital polymerase chain reaction (ddPCR). RESULTS: Of 266 included patients, estimated relapse-free survival (RFS) and overall survival (OS) rates 3 years after HSCT were 59% and 64%, respectively. MRD results were available for 221 patients. Relapse was preceded by positive BM MRD in 42/44 relapses with complete MRD data, by a median of 71 (23-283) days. Of 137 patients in continuous complete remission, 93 were consistently MRD-negative, 39 reverted from MRD+ to MRD-, and five were MRD+ at last sampling. Estimated 1 year-RFS after first positive MRD was 49%, 39%, and 30%, using cutoff levels of 0.1%, 0.3%, and 0.5%, respectively. In a multivariate Cox model, MRD (hazard ratio [HR], 7.99), WHO subgroup AML (HR, 4.87), TP53 multi-hit (HR, 2.38), NRAS (HR, 3.55), and acute GVHD grade III-IV (HR, 4.13) were associated with shorter RFS. MRD+ was also independently associated with shorter OS (HR, 2.65). In a subgroup analysis of 100 MRD+ patients, presence of chronic GVHD was associated with longer RFS (HR, 0.32). CONCLUSION: Assessment of individualized MRD using NGS + ddPCR is feasible and can be used for early detection of relapse. Positive MRD is associated with shorter RFS and OS (ClinicalTrials.gov identifier: NCT02872662).
引用
- Tobiasson M, Pandzic T, Illman J, et al. Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2024. PMID: 38232336. doi:10.1200/JCO.23.01159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。